{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:06:43Z","timestamp":1784524003894,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-86159-9","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T09:27:51Z","timestamp":1738574871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Personalized metronomic radiopharmaceutical therapy through injection profile optimization via physiologically based pharmacokinetic (PBPK) modeling"],"prefix":"10.1038","volume":"15","author":[{"given":"Aryan","family":"Golzaryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Moradi Kashkooli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Saboury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Rahmim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"86159_CR1","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1118\/1.3581059","volume":"38","author":"P Kletting","year":"2011","unstructured":"Kletting, P. et al. Optimal preloading in radioimmunotherapy with anti-CD45 antibody. Med. Phys. 38, 2572\u20132578 (2011).","journal-title":"Med. Phys."},{"key":"86159_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/ph15010013","volume":"15","author":"C Barca","year":"2021","unstructured":"Barca, C. et al. Expanding theranostic radiopharmaceuticals for tumor diagnosis and therapy. Pharmaceuticals 15, 13 (2021).","journal-title":"Pharmaceuticals"},{"key":"86159_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.7150\/thno.62851","volume":"12","author":"C Miller","year":"2022","unstructured":"Miller, C. et al. Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs. Theranostics 12, 232 (2022).","journal-title":"Theranostics"},{"key":"86159_CR4","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.2967\/jnumed.117.191023","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler, W. P., Rahbar, K., Herrmann, K., Kratochwil, C. & Eiber, M. 177Lu-PSMA radioligand therapy for prostate cancer. J. Nucl. Med. 58, 1196\u20131200 (2017).","journal-title":"J. Nucl. Med."},{"key":"86159_CR5","first-page":"P619","volume":"64","author":"A Golzaryan","year":"2023","unstructured":"Golzaryan, A., Soltani, M., Moradi Kashkooli, F., Uribe, C. & Rahmim, A. An in silico study quantifying the effects of reducing salivary gland blood flow on tumor to organ-at-risk absorbed dose ratios. J. Nucl. Med. 64, P619\u2013P619 (2023).","journal-title":"J. Nucl. Med."},{"key":"86159_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-00989-x","volume":"11","author":"F Moradi Kashkooli","year":"2021","unstructured":"Moradi Kashkooli, F. & Soltani, M. Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach. Sci. Rep. 11, 1\u201315 (2021).","journal-title":"Sci. Rep."},{"key":"86159_CR7","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.3390\/jcm11102853","volume":"11","author":"PJ Wysocki","year":"2022","unstructured":"Wysocki, P. J., Lubas, M. T. & Wysocka, M. L. Metronomic chemotherapy in prostate cancer. J. Clin. Med. 11, 2853 (2022).","journal-title":"J. Clin. Med."},{"key":"86159_CR8","doi-asserted-by":"crossref","unstructured":"Cazzaniga, M. E. et al. Metronomic chemotherapy. Cancers 13, 2236 (2021).","DOI":"10.3390\/cancers13092236"},{"key":"86159_CR9","doi-asserted-by":"crossref","unstructured":"He, L. et al. Metastatic castration-resistant prostate cancer: academic insights and perspectives through bibliometric analysis. Medicine 99 (2020).","DOI":"10.1097\/MD.0000000000019760"},{"key":"86159_CR10","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. & Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 3, 81\u201385 (1997).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"86159_CR11","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.3390\/cancers13163967","volume":"13","author":"M El Fakiri","year":"2021","unstructured":"El Fakiri, M., Geis, N. M., Ayada, N., Eder, M. & Eder A.-C. PSMA-targeting radiopharmaceuticals for prostate cancer therapy: recent developments and future perspectives. Cancers 13, 3967 (2021).","journal-title":"Cancers"},{"key":"86159_CR12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.zemedi.2013.03.005","volume":"23","author":"G Glatting","year":"2013","unstructured":"Glatting, G., Bardi\u00e8s, M. & Lassmann, M. Treatment planning in molecular radiotherapy. Z. Med. Phys. 23, 262\u2013269 (2013).","journal-title":"Z. Med. Phys."},{"key":"86159_CR13","doi-asserted-by":"publisher","first-page":"e20344","DOI":"10.1371\/journal.pone.0020344","volume":"6","author":"M Soltani","year":"2011","unstructured":"Soltani, M. & Chen, P. Numerical modeling of fluid flow in solid tumors. PloS One 6, e20344 (2011).","journal-title":"PloS One"},{"key":"86159_CR14","unstructured":"Glatting, G., Eiber, M. & Kletting, P. The effect of total tumor volume on the biologically effective dose to tumor and kidneys for 177 Lu-labeled."},{"key":"86159_CR15","doi-asserted-by":"publisher","first-page":"1062592","DOI":"10.3389\/fonc.2022.1062592","volume":"12","author":"A Rahmim","year":"2022","unstructured":"Rahmim, A. et al. Theranostic digital twins for personalized radiopharmaceutical therapies: reimagining theranostics via computational nuclear oncology. Front. Oncol. 12, 1062592 (2022).","journal-title":"Front. Oncol."},{"key":"86159_CR16","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2967\/jnumed.117.203505","volume":"59","author":"NJ Begum","year":"2018","unstructured":"Begum, N. J. et al. The effect of total tumor volume on the biologically effective dose to tumor and kidneys for 177Lu-labeled PSMA peptides. J. Nucl. Med. 59, 929\u2013933 (2018).","journal-title":"J. Nucl. Med."},{"key":"86159_CR17","doi-asserted-by":"publisher","first-page":"e0162303","DOI":"10.1371\/journal.pone.0162303","volume":"11","author":"P Kletting","year":"2016","unstructured":"Kletting, P. et al. Investigating the effect of ligand amount and injected therapeutic activity: a simulation study for 177Lu-labeled PSMA-targeting peptides. PLoS One. 11, e0162303 (2016).","journal-title":"PLoS One"},{"key":"86159_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2967\/jnumed.120.245068","volume":"62","author":"LD Jim\u00e9nez-Franco","year":"2021","unstructured":"Jim\u00e9nez-Franco, L. D. et al. Effect of tumor perfusion and receptor density on tumor control probability in 177Lu-DOTATATE therapy: an in silico analysis for standard and optimized treatment. J. Nucl. Med. 62, 92\u201398 (2021).","journal-title":"J. Nucl. Med."},{"key":"86159_CR19","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1002\/mp.13049","volume":"45","author":"LD Jim\u00e9nez-Franco","year":"2018","unstructured":"Jim\u00e9nez-Franco, L. D., Kletting, P., Beer, A. J. & Glatting, G. Treatment planning algorithm for peptide receptor radionuclide therapy considering multiple tumor lesions and organs at risk. Med. Phys. 45, 3516\u20133523 (2018).","journal-title":"Med. Phys."},{"key":"86159_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-56603-8","volume":"9","author":"NJ Begum","year":"2019","unstructured":"Begum, N. J. et al. The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: a simulation study using a PBPK model. Sci. Rep. 9, 1\u20138 (2019).","journal-title":"Sci. Rep."},{"key":"86159_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-021-00821-7","volume":"11","author":"H Siebinga","year":"2021","unstructured":"Siebinga, H. et al. A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68 Ga-DOTATATE in patients without neuroendocrine tumors. EJNMMI Res. 11, 1\u201312 (2021).","journal-title":"EJNMMI Res."},{"key":"86159_CR22","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/mp.14622","volume":"48","author":"D Hardiansyah","year":"2021","unstructured":"Hardiansyah, D. et al. Important pharmacokinetic parameters for individualization of 177Lu-PSMA therapy: a global sensitivity analysis for a physiologically\u2010based pharmacokinetic model. Med. Phys. 48, 556\u2013568 (2021).","journal-title":"Med. Phys."},{"key":"86159_CR23","first-page":"113","volume":"6","author":"KP Willowson","year":"2018","unstructured":"Willowson, K. P. et al. A comparison of 2D and 3D kidney absorbed dose measures in patients receiving 177Lu-DOTATATE. Asia Ocean. J. Nucl. Med. Biol. 6, 113 (2018).","journal-title":"Asia Ocean. J. Nucl. Med. Biol."},{"key":"86159_CR24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2967\/jnumed.115.164699","volume":"57","author":"P Kletting","year":"2016","unstructured":"Kletting, P. et al. Optimized peptide amount and activity for 90Y-labeled DOTATATE therapy. J. Nucl. Med. 57, 503\u2013508 (2016).","journal-title":"J. Nucl. Med."},{"key":"86159_CR25","first-page":"90","volume":"4","author":"R Gospavic","year":"2016","unstructured":"Gospavic, R., Knoll, P., Mirzaei, S. & Popov, V. Physiologically based pharmacokinetic (PBPK) model for biodistribution of radiolabeled peptides in patients with neuroendocrine tumours. Asia Ocean. J. Nucl. Med. Biol. 4, 90 (2016).","journal-title":"Asia Ocean. J. Nucl. Med. Biol."},{"key":"86159_CR26","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00259-015-3248-6","volume":"43","author":"D Hardiansyah","year":"2016","unstructured":"Hardiansyah, D. et al. The role of patient-based treatment planning in peptide receptor radionuclide therapy. Eur. J. Nucl. Med. Mol. Imaging 43, 871\u2013880 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"86159_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ejmp.2017.06.024","volume":"42","author":"D Hardiansyah","year":"2017","unstructured":"Hardiansyah, D., Attarwala, A. A., Kletting, P., Mottaghy, F. M. & Glatting, G. Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic model. Phys. Med. 42, 298\u2013304 (2017).","journal-title":"Phys. Med."},{"key":"86159_CR28","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1118\/1.4961012","volume":"43","author":"D Hardiansyah","year":"2016","unstructured":"Hardiansyah, D., Guo, W., Kletting, P., Mottaghy, F. M. & Glatting, G. Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: a simulation study on the effect of sampling schedule and noise. Med. Phys. 43, 5145\u20135154 (2016).","journal-title":"Med. Phys."},{"key":"86159_CR29","doi-asserted-by":"crossref","unstructured":"Brosch-Lenz, J., Uribe, C., Rahmim, A. & Saboury, B. Theranostic digital twins: an indispensable prerequisite for personalized cancer care. J. Nucl. Med. (2023).","DOI":"10.2967\/jnumed.122.264929"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86159-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86159-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86159-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T21:03:09Z","timestamp":1738616589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86159-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["86159"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-86159-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"29 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4052"}}